Jon Napitupulu

Trevi Therapeutics has secured end-of-Phase 2 alignment with FDA for Haduvio (oral nalbuphine ER) in idiopathic pulmonary fibrosis (IPF)-related...

CytomX Therapeutics has launched a $250 million underwritten public offering of common stock, with an additional 30-day option for...

Rhythm Pharmaceuticals reported topline results from EMANATE, a global, randomized, double-blind, placebo-controlled Phase 3 trial of setmelanotide in rare,...

Fennec Pharmaceuticals has settled its patent litigation with Cipla over a proposed generic of Pedmark, securing an agreement that...

CytomX Therapeutics reported a positive Phase 1 dose-expansion update for varsetatug masetecan, an EpCAM-targeted Probody ADC, in advanced colorectal...

Zenas Biopharma will file a U.S. BLA for obexelimab in IgG4-related disease in Q2 2026, with an EMA submission...

Akari Therapeutics has marked its first year under new leadership with a reset around antibody-drug conjugates, unveiling concrete steps...

Barinthus Biotherapeutics plans to merge with Clywedog Therapeutics in an all-stock deal expected to close in the second quarter...

Eupraxia Pharmaceuticals reported fourth quarter 2025 results, pairing positive clinical signals from its eosinophilic esophagitis program with strengthened finances....

Tonix Pharmaceuticals has turned the corner from development to commercialization with the U.S. launch of Tonmya, a sublingual cyclobenzaprine...